Clinical Research Directory
Browse clinical research sites, groups, and studies.
Individualized Genotype-guided Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Sponsor: Medisch Spectrum Twente
Summary
Rationale Patients diagnosed with acute coronary syndrome (ACS), a sudden medical emergency where blood flow to the heart is blocked, require dual antiplatelet therapy (DAPT) for 12 months to prevent dangerous blood clots to form. This typically includes the combination of aspirin and a form of P2Y12 inhibitor, a specific type of medicine that stops platelet cells to clot. Irrespective of the treatment strategy (i.e., invasive through angioplasty or conservative with medication only), the somewhat more potent P2Y12 inhibitor ticagrelor is advised over clopidogrel. Yet, clopidogrel can be considered for patients with a higher bleeding risk, as it is associated with fewer bleeding events. Although ischemic complications (problems that happen when the heart doesn't get enough blood and oxygen) usually appear in the first 30 days after ACS diagnosis, the bleeding risks remains high through the entire period of DAPT. A de-escalation strategy (switch from ticagrelor to clopidogrel after 30 days) could theoretically reduce the number of bleeding events, without increasing the number of ischemic events. However, in 30% of the (white) European patients, there is a small change (mutation) in their genetic material. They are carriers of at least one so called CYP2C19 loss-of-function (LOF) allele, which results in a poor or intermediate processing of clopidogrel in to its active form. Despite knowledge of these loss of function mutations, current treatment guidelines for ACS do not provide specific recommendations on individualized, genotype-based treatment (i.e. using the unique genetic code to choose the medicine that works best) with P2Y12 inhibitors. In addition, previous conducted trials on a de-escalation strategy have not led to strong recommendations, as they were too small and cautious to give definite answers. Objective The goal of this clinical trial is to investigate whether individualized genotype-guided treatment with DAPT after ACS diagnosis is just as safe and effective as standard clinical practice. Participants will receive: 1. Standard treatment at the discretion of the cardiologist, or 2. Genotype-guided treatment (based on the presence of a LOF allele) Participants included in the genotype-guided group who do not carry a LOF allele will be classified as normal processors of clopidogrel, and will de-escalate after 30 days from standard therapy to clopidogrel. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place and treatment will continue as previously started. Participants will be followed for 18 months after ACS diagnosis to collect medical data and to complete questionnaires.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3120
Start Date
2026-11-15
Completion Date
2030-03-01
Last Updated
2026-11-16
Healthy Volunteers
No
Conditions
Interventions
Genotype guided P2Y12 therapy
All patients with ACS can be enrolled. Randomization will take place at time of ACS diagnosis. For the first 30 days after the index event, patients will be treated with DAPT as prescribed by the cardiologist. Patients who experience a major event (any death, spontaneous MI, definite stent thrombosis, any stroke, and major bleeding) during the first 30 days will be excluded from the main analysis. For these patients, DAPT treatment will remain unchanged. Included patients will be randomly assigned (1:1) to: 1. Standard treatment at the discretion of the cardiologist 2. Genotype-guided treatment In the patients randomized to the intervention arm genotyping will be performed and patients who do not carry a LOF allele will be classified as normal or ultrafast metabolizers. In these patients, de-escalation of P2Y12 inhibitor from standard therapy to clopidogrel will be performed around 30 days. If patients are proven carriers of one of the LOF alleles, de-escalation will not take place.
Standard therapy group
Patients randomized for the standard therapy arm will receive dual antiplatelet therapy at the descretion of the cardiologist
Locations (2)
Ziekenhuis Groep Twente
Almelo, Overijssel, Netherlands
Medisch Spectrum Twente
Enschede, Overijssel, Netherlands